Policy on Access to
Investigational Therapies

Human Immunology Biosciences, Inc. (HI-Bio™) leverages human genetic and immunological insights to deliver targeted therapies to patients with severe immune-mediated diseases (IMDs). 

At this time, HI-Bio does not provide access to investigational products outside of clinical trials. We encourage patients to participate in clinical trials of our investigational therapies whenever possible because clinical trials are designed, conducted, and monitored to ensure that the safety and efficacy of these therapies are appropriately evaluated - before they are submitted to regulatory agencies for review with the intent to make them more broadly available to patients.

You and your health care provider may learn more about our clinical trials by going to the pipeline section of our website or visiting www.clinicaltrials.gov and searching for “HI-Bio” under “Other terms” or the name of a therapy (e.g., “felzartamab”) under “Intervention/Treatment.”

If you are a health care provider who is interested in learning more about one of our investigational therapies, or a physician with questions about participation in one of our clinical trials, please submit a request to medinfo@hibio.com. The company will acknowledge questions as soon as possible with the aim of responding no less than five (5) business days after receipt.

If applicable, this website will be updated with hyperlinks to the relevant expanded access information on www.clinicaltrials.gov upon activation. HI-Bio reserves the right to revise this expanded access policy at any time.